(Reuters) -The U.S. Food and Drug Administration has declined to approve PTC Therapeutics’ drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday, delaying a potential treatment for patients with limited treatment options.
(Reporting by Kamal Choudhury, Puyaan Singh and Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Comments